4//SEC Filing
Reich Kristian 4
Accession 0001213900-24-016240
CIK 0001821586other
Filed
Feb 21, 7:00 PM ET
Accepted
Feb 22, 6:32 PM ET
Size
12.1 KB
Accession
0001213900-24-016240
Insider Transaction Report
Form 4
Reich Kristian
Chief Scientific Officer
Transactions
- Sale
Class A ordinary shares, par value $0.0001 per share
2024-02-20$57.43/sh−10,000$574,300→ 100,071 total - Sale
Class A ordinary shares, par value $0.0001 per share
2024-02-21$55.31/sh−509$28,153→ 2,986,974 total(indirect: See footnote.) - Sale
Class A ordinary shares, par value $0.0001 per share
2024-02-20$57.45/sh−10,000$574,500→ 2,987,483 total(indirect: See footnote.) - Sale
Class A ordinary shares, par value $0.0001 per share
2024-02-21$55.30/sh−569$31,466→ 99,502 total
Footnotes (6)
- [F1]This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on October 16, 2023.
- [F2]The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $55.06 to $59.09. Upon request by the staff of the U.S. Securities and Exchange Commission (the "Commission"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- [F3]Represents the ordinary shares of the Issuer owned by JeruCON Beratungsgesellschaft mbH. Dr. Reich directly (whether through ownership or position) or indirectly through one or more intermediaries, may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the ordinary shares owned by JeruCON Beratungsgesellschaft mbH.
- [F4]The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $55.14 to $59.09. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- [F5]The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $55.225 to $55.33. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- [F6]The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $55.15 to $55.33. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Documents
Issuer
MoonLake Immunotherapeutics
CIK 0001821586
Entity typeother
Related Parties
1- filerCIK 0001920553
Filing Metadata
- Form type
- 4
- Filed
- Feb 21, 7:00 PM ET
- Accepted
- Feb 22, 6:32 PM ET
- Size
- 12.1 KB